



## Séminaires externes IRCM 2016

---

2016

**Vendredi 9 décembre 2016, 14h00**

Sophie Polo, Epigenetics and Cell Fate Centre, CNRS/Université Paris Diderot

**"Maintenance of epigenome integrity following DNA damage"**

Contact : [florence.cammas@inserm.fr](mailto:florence.cammas@inserm.fr)

---

**Vendredi 2 décembre 2016, 11h00**

Frédéric Thomas, MIVEGEC, IRD/CNRS/UM, Agropolis Montpellier

**"An evolutionary perspective of cancer."**

Contact : [florence.bernex@inserm.fr](mailto:florence.bernex@inserm.fr)

---

**Vendredi 30 septembre 2016, 11h00**



Conférence de "IRCM-SIRIC Montpellier-Cancer seminar series"

Jean-Christophe Marine, VIB Leuven University, Dept of Cancer Biology

**"Epigenetic drivers of Melanoma provide new therapeutic targets"**

Contact : [laurent.lecam@inserm.fr](mailto:laurent.lecam@inserm.fr)

---

**Vendredi 9 septembre 2016, 14h00**

Marie Dutreix, Institut Curie, Orsay

**"Combination of new DNA repair inhibitors AsidNA with radiotherapy"**

Contact : [david.azria@icm.unicancer.fr](mailto:david.azria@icm.unicancer.fr)

---

**Lundi 5 septembre 2016, 14h00**

Fred Dick, Western University, London, Ontario, Canada

**"Investigation of an RB dependent tumour suppression network"**

Contact : [laurent.lecam@inserm.fr](mailto:laurent.lecam@inserm.fr)

---

**Lundi 27 juin 2016, 14h00**

John H White, Mc Gill University, Montréal, Qc, Canada

**"Vitamin D Receptor Signaling in Immunity and Cancer"**

Contact : [vincent.cavaillès@inserm.fr](mailto:vincent.cavaillès@inserm.fr)

---

**Vendredi 24 juin 2016, 14h00**

Raul Duran, IECB, VINCO U916, Inserm, Bordeaux

**"Escaping mTOR inhibition in cancer therapy: tumor suppressor functions of mTOR"**

Contact : [laurent.lecam@inserm.fr](mailto:laurent.lecam@inserm.fr)

---

**Vendredi 17 juin 2016, 14h00**



Conférence de "IRCM-SIRIC Montpellier-Cancer seminar series"

**Carlos Caldas**, Professor of Cancer Medicine, Cancer Research UK Cambridge Institute

**"Unravelling the inter- and intra-tumour heterogeneity of breast cancer"**

Contact : [charles.theillet@inserm.fr](mailto:charles.theillet@inserm.fr)

---

**Vendredi 10 juin 2016, 14h00**

Eva Gonzalez-Suarez, IDIBELL, Barcelone

**"Exploring novel therapeutic opportunities of RANK pathway in cancer"**

Contact : [antonio.maraver@inserm.fr](mailto:antonio.maraver@inserm.fr)

---

**Jeudi 2 juin 2016, 14h00**

Montse Sanchez-Cespedes, Cancer Epigenetics and Biology, IDIBELL, Barcelone

**"The MYC/MAX and the SWI/SNF networks in lung cancer: biological understanding and therapeutic applications"**

Contact : [antonio.maraver@inserm.fr](mailto:antonio.maraver@inserm.fr)

---

**Vendredi 27 mai 2016, 14h00**

Gilles Favre, CRT, Toulouse

**"RAS related GTPase RHOB, a novel actor in lung cancer progression and treatment"**

Contact : [antonio.maraver@inserm.fr](mailto:antonio.maraver@inserm.fr)

---

**Mercredi 25 mai 2016, 11h00**



séminaire externe du LabEx MAbImprove

**Dr Ann Louise White**, 'Antibody and Vaccine Group' (Faculty of Medicine, Southampton University Hospital, UK)

**"Optimising CD40 antibodies for cancer therapy"**

Immunomodulatory mAb therapy is at the forefront of developing cancer therapeutics with numerous targeted agents proving highly effective in selective patients at stimulating protective host immunity. The engagement of immune co-stimulatory receptors such as CD40, a cell surface marker expressed on a range of immune and malignant cells, plays a critical role in modulating adaptive immune responses. In this context, anti-CD40 mAb therapy has been shown to act via multiple mechanisms to stimulate anti-tumour immunity across a broad range of lymphoid and solid malignancies. A wealth of preclinical research in this field has led to the successful development of multiple anti-CD40 mAb agents that have shown promise in early-phase clinical trials. Ann Louise White's studies aimed at understanding the molecular mechanisms that drive the therapeutic effects of anti-CD40 mAb. Notably, her recent data examined the role of mAb isotypes and Fc receptors interaction in dictating immunostimulatory and therapeutic activity of anti-CD40 mAb. Her work has important implications in the optimization of immunostimulatory agents through mAb engineering and it has been pivotal in delineating the molecular pathways that contribute to the mechanisms of action of different antibody drugs with direct implication for drug development.

---

**Vendredi 13 mai 2016, 14h00**

**Sylvie Chevillard**, Laboratoire de Cancérologie Expérimentale, IRCM-CEA, Fontenay aux Roses

**"Radiosensibilité des cancers du sein : marqueurs et modulation"**

Contact : [celine.bourgier@icm.unicancer.fr](mailto:celine.bourgier@icm.unicancer.fr)

---

**Mercredi 11 mai 2016, 11h00**

**Silvia Frei**, Developmental Biology and Genetics, Institut Curie, Paris

**"Defining cell lineage specification during mammary gland development"**

Contact : [alexandre.djjiane@inserm.fr](mailto:alexandre.djjiane@inserm.fr)

---

**Mercredi 27 avril 2016, 11h00**



séminaire externe du LabEx MAbImprove

**Timothée Bruel**, Laboratoire virus et immunité, institut Pasteur de Paris (CNRS PARIS 7 UMR3569)

## **"Elimination of HIV-1-infected cells by broadly neutralizing antibodies"**

Dr Timothée Bruel obtained his PhD in Microbiology and Immunology from Université Paris Sud (Paris XI, France) in 2012 where he worked on the role of Type I IFN and plasmacytoid dendritic cell in HIV primary infection. Currently, he's post doctoral researcher and is working on impact of immune response on HIV cell-to-cell transmission."

---

**Mercredi 13 avril 2016, 11h00**



séminaire externe du LabEx MAbImprove

**Professor Rajan Dighe,**

## **"Antibody-based targeting: experience with Notch, DEC205 and glycoprotein hormone receptors"**

Professor Rajan Dighe obtained a Ph.D. Biochemistry from the Indian Institute of Science in 1982. He then did his post doctoral training at Baylor College of Medicine and UT Medical School, Houston.

He later obtained a visiting Rockefeller Foundation fellow at the Population Council, Rockefeller University, NY.

Rajan Dighe joined the faculty of Indian Institute of Science in 1990 and is currently Professor at the Molecular Reproduction, Development and Genetics (MRDG). He served as Chairman of MRDG from 2005 to 2010.

He is fellow on Science Academies of India and has been awarded J.C.

Bose Fellowship. His scientific interest covers gonadotropins and their receptors, contraceptive vaccines for animals, Notch signaling and cancer immunotherapy.

Developing antibodies and scFvs against his targets of interest has long been central in his research.

---

**Mercredi 6 avril 2016, 14h00**

**Maria Vinci,** Divisions of Molecular Pathology and Cancer Therapeutics The Institute of Cancer Research, Sutton, GB

## **"Functional diversity and co-operativity in paediatric high grade gliomas"**

Contact : [maguy.delrio@icm.unicancer.fr](mailto:maguy.delrio@icm.unicancer.fr)

---

**Jeudi 31 mars 2016, 11h00**

**Philippe Barthélémy**, ChemBioPharm, INSERM U1212, Université de Bordeaux

**"Chimie des acides nucléiques pour la nanomédecine"**

The combination of nucleic acids chemistry (e.g., nucleoside, nucleotides, oligonucleotides) with supramolecular principles provides an efficient and powerful approach to prepare well-defined systems with tunable physico-chemical properties and functions. We develop new nano-systems based on nucleic acids chemistry for i) drug delivery applications (therapeutic, theranostic), and ii) tissue engineering. This communication will present novel "smart" nucleic acid derivatives (nucleolipids, lipid-oligonucleotide conjugates) developed in our lab.

Contact : [charles.theillet@inserm.fr](mailto:charles.theillet@inserm.fr)

---

**Vendredi 18 mars 2016, 11h00**



Conférence de "IRCM-SIRIC Montpellier-Cancer seminar series"

**Enzo Medico**, Candiolo Cancer Institute, Université de Turin, Italie

**"Colorectal cancer subtyping: from human tumors to preclinical models and back"**

Contact : [charles.theillet@inserm.fr](mailto:charles.theillet@inserm.fr)

---

**Lundi 7 mars 2016, 11h00**

**Paola ARIMONDO**, Epigenetic Targeting of Cancer, FRE3600 CNRS, Toulouse

**"Targeting DNA methylation to modulate gene expression in cancer cells"**

Contact : [charles.theillet@inserm.fr](mailto:charles.theillet@inserm.fr)

---

**Mercredi 10 février 2016, 11h00**



séminaire externe du LabEx MAbImprove

**Didier Boquet**, chercheur au CEA à Saclay,

**"L'axe endothéline, une opportunité pour l'immunothérapie de certains cancers"**

Après s'être consacré aux anticorps anti-récepteurs à la substance P, aux anticorps anti-protéine prion et à de nombreuses autres cibles, il démarre en 2007 un programme dédié à l'isolement d'anticorps anti-récepteurs A et B des endothélines (récepteurs RCPG), en procédant par immunisation génique, comme pour les anticorps contre le récepteur à la substance P. Il est l'auteur de 49 publications et 2 brevets.

---

**Jeudi 14 janvier 2016, 11h00**

**Béatrice ROMAGNOLO**, Institut Cochin, Equipe Oncogenèse des épithéliums digestifs - Paris

**"Rôle anti-tumoral de l'autophagie dans la cancérogène intestinale"**

Contact : [sophie.pattingre@inserm.fr](mailto:sophie.pattingre@inserm.fr)